Literature DB >> 17414233

Is it easier to find what you are looking for if you think you know what it looks like?

James C Mundt, John H Greist, James W Jefferson, David J Katzelnick, David J DeBrota, Phillip B Chappell, Jack G Modell.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17414233     DOI： 10.1097/JCP.0b013e3180387820

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  11 in total

Review 1.  Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations.

Authors:  Jennifer S Gewandter; Robert H Dworkin; Dennis C Turk; Eric G Devine; David Hewitt; Mark P Jensen; Nathaniel P Katz; Amy A Kirkwood; Richard Malamut; John D Markman; Bernard Vrijens; Laurie Burke; James N Campbell; Daniel B Carr; Philip G Conaghan; Penney Cowan; Mittie K Doyle; Robert R Edwards; Scott R Evans; John T Farrar; Roy Freeman; Ian Gilron; Dean Juge; Robert D Kerns; Ernest A Kopecky; Michael P McDermott; Gwendolyn Niebler; Kushang V Patel; Richard Rauck; Andrew S C Rice; Michael Rowbotham; Nelson E Sessler; Lee S Simon; Neil Singla; Vladimir Skljarevski; Tina Tockarshewsky; Geertrui F Vanhove; Ajay D Wasan; James Witter
Journal:  J Pain       Date:  2019-12-13       Impact factor: 5.820

2.  Vocal acoustic biomarkers of depression severity and treatment response.

Authors:  James C Mundt; Adam P Vogel; Douglas E Feltner; William R Lenderking
Journal:  Biol Psychiatry       Date:  2012-04-26       Impact factor: 13.382

Review 3.  A model of placebo response in antidepressant clinical trials.

Authors:  Bret R Rutherford; Steven P Roose
Journal:  Am J Psychiatry       Date:  2013-07       Impact factor: 18.112

4.  Antidepressants versus placebo in major depression: an overview.

Authors:  Arif Khan; Walter A Brown
Journal:  World Psychiatry       Date:  2015-10       Impact factor: 49.548

5.  The role of patient expectancy in placebo and nocebo effects in antidepressant trials.

Authors:  Bret R Rutherford; Melanie M Wall; Andrew Glass; Jonathan W Stewart
Journal:  J Clin Psychiatry       Date:  2014-10       Impact factor: 4.384

6.  A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.

Authors:  Atul R Mahableshwarkar; Paula L Jacobsen; Yinzhong Chen; Michael Serenko; Madhukar H Trivedi
Journal:  Psychopharmacology (Berl)       Date:  2015-01-11       Impact factor: 4.530

7.  One (effect) size does not fit at all: Interpreting clinical significance and effect sizes in depression treatment trials.

Authors:  Fredrik Hieronymus; Sameer Jauhar; Søren Dinesen Østergaard; Allan H Young
Journal:  J Psychopharmacol       Date:  2020-05-25       Impact factor: 4.153

8.  The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients.

Authors:  Yoshifumi Koshino; Won-Myong Bahk; Hideaki Sakai; Takayuki Kobayashi
Journal:  Neuropsychiatr Dis Treat       Date:  2013-08-28       Impact factor: 2.570

Review 9.  Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder.

Authors:  Enric Alvarez; Victor Perez; Francesc Artigas
Journal:  Neuropsychiatr Dis Treat       Date:  2014-07-15       Impact factor: 2.570

10.  John D. Loeser Award Lecture: Size does matter, but it isn't everything: the challenge of modest treatment effects in chronic pain clinical trials.

Authors:  Shannon M Smith; Maurizio Fava; Mark P Jensen; Omar B Mbowe; Michael P McDermott; Dennis C Turk; Robert H Dworkin
Journal:  Pain       Date:  2020-09       Impact factor: 7.926
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.